Personalizing treatment for narcolepsy requires shared decision-making between patients and clinicians to understand the most important symptoms that need to be treated and the right therapy, said Michael Thorpy, MD, director of the Sleep-Wake Disorders Center at Montefiore Medical Center and professor of neurology at Albert Einstein College of Medicine.
Personalizing treatment for narcolepsy requires shared decision-making between patients and clinicians to understand the most important symptoms that need to be treated and the right therapy, said Michael Thorpy, MD, director of the Sleep-Wake Disorders Center at Montefiore Medical Center and professor of neurology at Albert Einstein College of Medicine.
Transcript
How can clinicians ensure their patients’ voices are heard when it comes to aligning treatment goals for narcolepsy?
We're really entering into a stage of personalized medicine for patients with narcolepsy, and it's most important that clinicians really listen to their patients, understand the symptoms that they're having, the severity of those symptoms, and which are the most important ones. Narcolepsy has a number of different symptoms associated with it—there can be the excessive daytime sleepiness, the cataplexy, or the disturbed nocturnal sleep. And it's good for the clinician to recognize which of those conditions most affect the patient, and which are the ones that the patient feels that they need to get under control.
Because the management of narcolepsy involves a lot of new medications, it's important that the patient understands the differences between the medications and the treatments that are available to them. The clinician really needs to move into shared decision-making with the patient when it comes to the management of narcolepsy. Very often the treatment of narcolepsy involves not just one medication, but it may involve multiple medications. The patients need to understand that as to the interactions potentially, between these medications, and the interactions with other medications that they may be taking.
Narcolepsy is also associated with a lot of comorbidity illnesses—psychiatric illnesses, anxiety, and depression. Patients may be on medications to treat those conditions, and patients need to understand how their narcolepsy medications will interact with those medications. There's also new evidence with regards to comorbidities and cardiovascular disorders and some of the newer medications that can have an adverse effect upon cardiovascular parameters.
So, again, the most important thing in treating patients is to have that patient involvement and their understanding of not only the symptoms but also the treatments that are available, and then join into a shared decision-making process to get the best treatment for them.
How can clinicians encourage their patients to share as much as possible about the symptoms they are experiencing?
The important thing is education. A lot of patients with narcolepsy really don't understand the symptoms, and they've often lived with them for a number of years. They may underestimate the effect of these symptoms upon their daily life. It's important for the physician to address the different symptoms of narcolepsy and to see how they impact the patient's quality of life, their work, and their interpersonal relationships. So, discussing the impact of those symptoms is the most important thing in deciding which is the best direction to go in terms of management.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AUA to Focus on Inclusive Care, Robotic Surgeries, and Future of Urology at 2024 Annual Meeting
May 1st 2024The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for providers, and discussions on cutting-edge treatments and global health initiatives.
Read More
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AUA to Focus on Inclusive Care, Robotic Surgeries, and Future of Urology at 2024 Annual Meeting
May 1st 2024The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for providers, and discussions on cutting-edge treatments and global health initiatives.
Read More
2 Commerce Drive
Cranbury, NJ 08512